Ligand id: 6779

Name: ranibizumab

No information available.
Summary of Clinical Use
Used to treat macular edema after retinal vein occlusion, age-related (wet) macular degeneration, and diabetic macular edema. Administered by intravitreal injection.
In February 2015, the US FDA expanded approval to include treatment of diabetic retinopathy. FDA approval was further expaned to include myopic choroidal neovascularization (mCNV; a complication of severe near-sightedness that can lead to blindness) in January 2017.
Mechanism Of Action and Pharmacodynamic Effects
Binds to and inhibits the biologic activity (neo-vascularisation/vessel permeabiity) of active forms of human vascular endothelial growth factor A [3].
External links